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Background: Medication non-adherence is considered an important cause of morbidity and mortality in primary
care. This study aims to determine the effectiveness, cost effectiveness and acceptability of a complex intervention
delivered by community pharmacists, the New Medicine Service (NMS), compared with current practice in reducing
non-adherence to, and problems with, newly prescribed medicines for chronic conditions.
Methods/design: Research subject group: patients aged 14 years and above presenting in a community pharmacy
for a newly prescribed medicine for asthma/chronic obstructive pulmonary disease (COPD); hypertension; type 2
diabetes or anticoagulant/antiplatelet agents in two geographical regions in England.
Design: parallel group patient-level pragmatic randomized controlled trial.
Interventions: patients randomized to either: (i) current practice; or (ii) NMS intervention comprising pharmacist-
delivered support for a newly prescribed medicine.
Primary outcomes: proportion of adherent patients at six, ten and 26 weeks from the date of presenting their
prescriptions at the pharmacy; cost effectiveness of the intervention versus current practice at 10 weeks and
26 weeks; in-depth qualitative understanding of the operationalization of NMS in pharmacies.
Secondary outcomes: impact of NMS on: patients’ understanding of their medicines, pharmacovigilance,
interprofessional and patient-professional relationships and experiences of service users and stakeholders.
Economic analysis: Trial-based economic analysis (cost per extra adherent patient) and long-term modeling of costs
and health effects (cost per quality-adjusted-life-year) will be conducted from the perspective of National Health
Service (NHS) England, comparing NMS with current practice.
Qualitative analysis: a qualitative study of NMS implementation in different community settings, how organizational
influences affect NMS delivery, patterns of NMS consultations and experiences of professionals and patients
participating in NMS, and patients receiving current practice.
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Sample size: 250 patients in each treatment arm would provide at least 80% power (two-tailed alpha of 0.05) to
demonstrate a reduction in patient-reported non-adherence from 20% to 10% in the NMS arm compared with
current practice, assuming a 20% drop-out rate.
Discussion: At the time of submission of this article, 58 community pharmacies have been recruited and the
interventions are being delivered. Analysis has not yet been undertaken.
Trial registration: Current controlled trials: ISRCTN23560818
Clinical Trials US (clinicaltrials.gov): NCT01635361Background
Favorable outcomes in long-term conditions depend on
self-management by patients, including appropriate medi-
cines use. About 25% of medicines prescribed for long-
term conditions are not taken as directed [1,2], and 15% of
people receiving new medicines take few, if any, doses [3].
Many have problems with their medicines and have infor-
mation needs, but often fail to discuss these concerns with
their prescriber. Furthermore, prescribers do not ask
about, and so are generally unaware of, patients’ behavior
regarding following instructions, experimentation and
self-medication with other therapies [4,5]. Prescribers may
overestimate adherence [6], and be reluctant to voice sus-
picions about non-adherence [7]. Harm caused by non-
adherence includes poor health-related quality of life,
increased hospitalizations and premature mortality [8-11].
Wider burden includes cost to patients, healthcare pro-
viders and society. Improving adherence in asthma, type 2
diabetes and hypertension could save the English National
Health Service (NHS England) £290 million, annually [12].
Definition of adherence
In this study we have taken the definition of adherence
from the World Health Organization: ‘the extent to
which a person’s medication-taking behavior, following a
diet, and/or executing lifestyle changes, corresponds
with agreed recommendations from a healthcare pro-
vider’ [2]. In this study we operationalize adherence be-
havior by defining a patient as non-adherent if any
scheduled doses were missed at various time points as a
result of different adherence measures deployed.
Pharmacist-provided interventions to improve medicines use
Pharmacist-provided interventions exist to facilitate im-
proved medicines usage and health outcomes [13-26]. They
are also viewed by some as a means to enhance pharmacist
professional status [27]. Some interventions are effective
[13-15,25,26], but not all [20,22-24]. There is little evidence
around cost effectiveness of clinical community pharmacy
interventions [28-30]. Most studies have methodological
limitations: absence of a control, exclusion of pharmacist
employment cost, use of intermediate outcomes, exclusion
of health benefits, and absence of incremental analysis[28,31]. Interventions to improve medicines adherence have
been disappointing in producing sustained behavior change
[32], consistent health benefits, [33] or demonstrable cost
effectiveness [31,34]. This can be attributed to poor study
design, not using evidence on reasons for non-adherence,
poor intervention development, lack of understanding of
intervention complexity and its effects, and lack of integra-
tion into service delivery [35-37].
Implementing clinical services run by community phar-
macists has been hampered by insufficient integration into
patient pathways; poorly developed relationships between
pharmacists and general practitioners (GPs); lack of access
to patient information; inadequate methods for targeting
services; and pharmacists’ lack of willingness to provide the
service [38]. Medicines Use Reviews (MURs) are a recent
example of a community pharmacy-based intervention.
However, there has been variable uptake of MURs, mostly
in chain pharmacies [39-41]. MURs have been carried out
to variable standards by pharmacists, [42,43], partly due to
variable understanding of what constitutes an MUR [44].The New Medicine Service
The New Medicine Service (NMS) [45] in England is based
on evidence derived from our research that studied doctor-
patient communication concerning medicines [46-49]. This
and subsequent work established that problems with newly
prescribed medicines appeared rapidly, were widespread
and that a significant proportion of patients on a long-term
medication quickly become non-adherent [50]. A pharma-
cist’s intervention could significantly reduce reported prob-
lems and non-adherence in a cost effective manner [51,52].
Within the NHS community pharmacy contract, the NMS
is classified as an Advanced Service, whereby community
pharmacists can opt to provide the service from their phar-
macy [45]. This comes at a time when efficient medicines
use could not be more important, in the face of economic
pressures on the public sector budget. England’s ageing
population now receives 50% more prescriptions items per
capita for conditions such as heart disease, stroke, diabetes,
COPD and asthma than in 1990 [53]. This proposed study
is therefore timely as it is essential to evaluate whether
NMS is effective, cost effective and acceptable to patients
and healthcare providers. Supplementary policy-relevant
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regarding lifestyle and potential improved tracking of
medicines-related adverse events by community pharma-
cists and patients [54].
Aims of the study
The aims of this study are to:
 evaluate effectiveness and cost effectiveness of the
NMS, from an NHS perspective, to inform decisions
about continuation of the service
 explore operation of the NMS to determine
acceptability to patients, pharmacists and GPs,
indicators of successful implementation,
generalizability and replicability across four
therapeutic groupings in multiple pharmacy settings
Specific objectives
This study has two work streams: an RCTand a qualitative
investigation/appraisal. The purpose of the RCT is to
evaluate effectiveness and cost effectiveness of the NMS
from an NHS perspective to inform decisions about con-
tinuation of the service.
Data collected from the RCT will be used to:
 evaluate the impact of the NMS on patient
medicines-taking behavior, patient outcomes, and
cost effectiveness from an NHS perspective
 determine patients’ understanding of their medicines
and the extent to which they are informed and
supported in their medicines-related behavior
 examine whether NMS encourages
pharmacovigilance by community pharmacists
and patients
 inform and support future implementation and
support development of outcome and quality
measures for community pharmacy
The purpose of the qualitative workstream is to under-
stand how NMS is implemented and experienced as a
situated complex healthcare intervention. This involves
investigation and analysis of:
 the implementation of NMS in different community
pharmacy settings to determine the influence of
local organizing factors
 the organization and configuration of NMS in
different community pharmacies to determine
variation in NMS operation and delivery
 the delivery of the NMS as a situated social practice,
including interactions between multiple stakeholders
(GP-pharmacist; pharmacist-patient; patient-pharmacist)
 the experiences and reflections of professionals and
patients involved in the NMSEvidence generated will allow better understanding of
results obtained from both technology appraisal and
NMS audit, through providing detailed case evidence of
how and why the NMS is implemented in practice, in-
cluding variations in implementation and uptake.
Methods/design
Trial design
This study will involve community pharmacies in England.
It is a multi-center, pragmatic RCT involving a parallel
group design. The health technology appraisal will assess
the effectiveness and cost effectiveness of NMS via a
patient-level pragmatic RCT of NMS versus current prac-
tice combined with modeling of long-term economic im-
pact. Results generated from the technology appraisal will
be combined with NMS audit data to provide wider esti-
mates of effectiveness and cost effectiveness.
Qualitative study design
The qualitative workstream comprises three distinct re-
search activities:
a) pharmacy profiling will generate data on the
organizational variables associated with the
implementation, configuration and delivery NMS.
Profiling will involve ethnographically informed
observations and semi-structured interviews within
participating community pharmacies, including non-
participatory observations of work organization and
pharmacy practice, guided tours, shadowing of phar-
macy staff and interviews with pharmacy staff over a
three to five day period. Observations will be guided
by a standardized profiling tool to acquire common
data set from across different sites.
b) patient tracking will generate data on the real-time
delivery of NMS as a situated social interaction.
Based upon pharmacy profiles, it involves producing
a descriptive understanding of the ‘expected’ patient
pathway to identify key interaction, communication
and decision-making points followed by focused ob-
servations of, and interviews with, pharmacist and
patient ‘before’, ‘during’ and ‘after’ the NMS consult-
ation. A range of methods of recording data will be
offered to participants, including video and audio re-
cording or direct observation by research staff. Par-
ticipant patients to be tracked will be recruited via
the patient pool from the RCT.
c) stakeholder interviews will generate additional
qualitative understanding on the organization and
experience of NMS from the perspective of
community pharmacy staff including pharmacists,
dispensers and technicians. Patients who decline the
invitation for an NMS in the pharmacy will also be
invited to take part in short semi-structured
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one-to-one interviews will be conducted with pa-
tients whose voices are seldom heard, and pharma-
cist and GP interviews will also be conducted to
explore the professional perspective of the NMS.
Eligibility for pharmacies to join the trial
Community pharmacies providing NMS in East Midlands
and South Yorkshire (EMSY) and Greater London (GL)
are eligible. Pharmacy selection will take into account
known variables that influence organizational structures,
workflow and integration, including:
 ownership: independent; small multiple; large
multiple; supermarket
 proximity to GP: co-location; less than 500 meters;
500 meters to one km; over one km
 setting: urban; suburban; rural
 economic deprivation: based on Economic
Deprivation Index
Inclusion criteria
Community pharmacies will be eligible to take part in
the RCT if they meet the following criteria:
 they provide care for patients starting a new
medicine for one of four therapeutic groups:
asthma/chronic obstructive pulmonary disease
(COPD), type 2 diabetes, antiplatelets/anticoagulants
or hypertension
 they are able to understand the participant study
documents
 they are able and willing and able to provide consent
 they are accredited to provide the New Medicines
Service
Exclusion criteria
Community pharmacies will not be eligible to take part
in the RCT if:
 they are outside of the EMSY and GL area
 they currently do not provide NMS or undertake an
insufficient number to ensure recruitment to the
study (< two per week).
 the pharmacy does not have a regular pharmacist
(working on most days)
 the pharmacist is unable or unwilling to provide consent
Eligibility for patients to join the trial
Patient inclusion criteria
The study will include:
 community dwelling patients eligible for the NMS
(starting a new medicine for asthma/COPD, type 2diabetes, antiplatelet/anticoagulation or
hypertension)
 participants who are able to understand and consent
to the NMS and also the study and who are willing
to provide written consent/assent.Patient exclusion criteria
 those not eligible for the NMS such as
 patients collecting a repeat prescription for a
medicine (that is, not new)
 patients collecting a medicine where the only
change from the previous medicine involves a
dosage or formulation change only
 participants who are unable to understand patient/
participant study documents
 participants who are unable and unwilling to
provide written consent/assent
 those patients aged 13 and underRecruitment
Community pharmacies
Pharmacies will be recruited using a pragmatic convenience
sample to enable a representative sample across the four eli-
gibility criteria (ownership, proximity to the GP, setting, and
economic deprivation). Local pharmaceutical committees
and other regional and national pharmacy bodies in the GL
and EMSY have been approached to assist in finding suit-
able research sites, as were the superintendent pharmacists
of a range of multiple-owned pharmacy organizations.Patients for RCT
The initial approach to participants will be from the
community pharmacy that is providing the patient with
NMS. Patients who have consented to the NMS will be
invited to take part in the study. It will be explained to
patients that taking part in the study is optional and if
they decide not to take part they will be offered the
NMS service as normal.
The study-designated pharmacist will inform the pa-
tient or their nominated representative (other individual
or other body with appropriate jurisdiction), of all as-
pects pertaining to participation in the study. If the pa-
tient agrees to take part, the pharmacist will randomize
the patient to receive the NMS or allocated to receive
current practice. Patients could, if they were eligible for
the NMS, volunteer for the study once they have seen
the study poster displayed in the pharmacy. If a study-
designated pharmacist is not present in the pharmacy at
the time the patient presents with a prescription for a
new medicine eligible for the NMS, the patient cannot
be recruited into the study.
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Pharmacy profiles Twenty pharmacies will be recruited
for pharmacy profiling from those sites recruited to the
RCT. These community pharmacies will be selected
across geographical areas with the intention of investi-
gating differences in pharmacy type, location, ownership,
organization, and staffing.
Patient tracking Participants will be identified and their
NMS consultation recorded from a range of pharmacies
and patient characteristics. Written informed consent
will be taken before undertaking observation and inter-
views. The first two patients recruited into the study in
each pharmacy will not be considered for tracking to
allow the study pharmacist opportunity to familiarize
themselves with the study paperwork.
Semi-structured interviews will be undertaken with
community pharmacy and GP staff. A purposive sam-
pling strategy will be used to identify and recruit a range
of participants linked to the participating pharmacies:
pharmacists, pharmacy technicians, counter assistants,
GPs, nurse prescribers and patients in both geographical
regions. Written informed consent will be obtained be-
fore interviews will take place.
Interventions
Current practice
Those patients randomized to this arm will receive
current practice where the patient receives their pre-
scription, with advice as clinically necessary from the
pharmacist at point of supply. It is not routine for pa-
tients to have any follow-up in this arm. Patients in this
arm are not restricted from contacting the pharmacist
for advice should they wish to.
NMS intervention
Those patients randomized to this arm will receive the
NMS. The NMS will be offered by community phar-
macists to people starting a new medicine for asthma/
COPD, type 2 diabetes, hypertension or antiplatelet/
anticoagulant treatment. The NMS can be summarized
as patient engagement, intervention and follow-up
(Figure 1). This is described in the NMS service speci-
fication [45].
Study pharmacist training
All pharmacists who would be recruiting and consent-
ing patients to be in the study will be required to at-
tend a one day face-to-face training session at one of
the host institutions. Training will be delivered by the
study team and includes an overview of the study,
study aims and objectives, research governance (in-
cluding principles of Good Clinical Practice (GCP)),conducting the study in your pharmacy and interactive
practice sessions.
Pharmacist study training will be followed up by an
abridged training session in each pharmacy. This train-
ing provides all staff members with an overview of the
study and enables them to assist the pharmacist in iden-
tifying potential study participants.Allocation of trial intervention
Following the consenting process, patients will be random-
ized into their respective study groups. The randomization
sequence will be generated by the study statistician (RM).
Patients will be 1:1 randomized into one of the two
study arms stratified by drug/disease group within each
pharmacy using the SAS statistical software (version 9)
(SAS UK Headquarters Wittington House Henley Road
Medmenham Marlow, Buckinghamshire SL7 2 EB).
Block randomization at the pharmacy level is necessary
to avoid imbalances due to individual pharmacy vari-
ability. Separate randomization sequences were pro-
duced for patients 16 years and over and for patients
aged 14 and 15 years old. The separation by age is re-
quired as study documents for the 14 and 15 year-old
group include patient assent and parental consent in-
stead of the usual normal patient consent forms. It is
anticipated that there will be an unequal distribution
across the four groups; therefore, stratification by drug/
disease group is necessary, each with a different base-
line adherence and/or effect size. The intervention arm
will receive the NMS as per service specification while
the control arm will receive care as per current prac-
tice. Concealment of sequence allocation will be
achieved as pharmacists will randomly allocate patients
to the two study arms using disease and age group spe-
cific, sequentially numbered tamper-proof opaque
sealed envelopes containing details of allocation group.
Periodic checks will be undertaken by a researcher to
assess the integrity of study sites adhering to the
randomization procedures. The sequence of treatment
allocations will remain concealed until analysis is com-
pleted. Exceptions to this will include the need to re-
veal the randomization code because the patient has
been identified as suitable for the qualitative work
stream. As patients are registered into the study, checks
will be conducted to ensure compliance with the regis-
tration protocol.Outcome measures
A successfully implemented NMS has five levels (see
Figure 2) [55].
A summary of outcome measures, at which time
points they are collected, and the method of collection is
provided in Table 1.
InterventionEngagement Follow Up
GP referral to 
community 
pharmacist 
for NMS
Patient 
identified by 
community 
pharmacist for 
NMS
Refer to GP to 
resolve 
medicines-
related issues
7-14 
days
14-21 
days
Patient agrees to 
adhere to new 
medicine or 
pharmacist to 
resolve medicines-
related issues
Patient 
agrees to 
adhere to 
new 
medicine
Refer to GP to 
resolve 
medicines-
related issues
Figure 1 NMS intervention.
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The primary endpoint for the RCT is to establish the
impact of the NMS on patient medicines-taking behavior
through measurement of self-reported adherence. The
adherence measure in the interview schedule for the
NMS intervention [56] and follow-up interview is a sim-
ple question: ‘People often miss taking doses of theirCognitive 
Behaviou
Health outc
Health c
resource
Information provided 
to patients could 
change how perceive 
their medicines, 
beliefs, or result in 
increase in knowledge
NMS Interven
Figure 2 Intended outcomes of NMS intervention.medicines, for a wide range of reasons. Have you missed
any doses of your new medicine, or changed when you
take it? (Prompt: when did you last miss a dose?)’
Adherence in our original work was measured using
self-report [57], using a similar question to that in the
NMS interview. The patient was defined as non-
adherent if any doses were missed in the previous sevenEmotional/affective
ral
omes
are 
 use
Increasing confidence or 
motivation to take the 
medicine, feeling reassured 
that care is being provided, 
increased sense of 
satisfaction
Increased adherence
Improved health -related 
quality of life
Value for money
tion
Table 1 Summary of outcome measures
Outcome measure Time point
recorded
Method of
recording
Health status 0 weeks Questionnaire
EuroQol-5 dimension-3 6 weeks
Level instrument 10 weeks
(EQ-5D-3 L) 26 weeks
Adherence 6 weeks Questionnaire
Morisky’s medication 10 weeks
Adherence scale 8-item
version (MMAS-8)
26 weeks
Adherence 6 weeks Questionnaire
Visual analogs scale 10 weeks
(VAS) 26 weeks
Adherence 6 weeks Telephone interview
NMS service question 10 weeks
26 weeks
Medicines 6 weeks Questionnaire
Understanding 10 weeks
Beliefs About Medicines
Questionnaire (BMQ)
26 weeks
Consultation satisfaction 6 weeks Questionnaire
Medical interview satisfaction
scale-15
(MISS-15)
Health resource use 0 to 26 weeks
inclusive
Self-completed diary
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adherence will identify at least 50% of those with low ad-
herence, with a specificity of 87% [58]. We will validate
the NMS adherence measure by using an existing vali-
dated scale alongside it (Morisky Eight Item Medication
Adherence Scale (MMAS-8)) [59].
Secondary outcome measures
We are collecting data on a number of secondary out-
come measures relating to number of medicines-related
problems reported by patients, and resolved; adverse
events and NHS contacts associated with adverse events;
health status; resource use and costs; length of initial
and subsequent NMS consultations; NHS contact (pri-
mary and secondary care) and non-medical costs.
Composite outcomes
In the original work, most ‘withdrawals’ were that the
patients in the intervention arm were referred back to
the GP by the pharmacist due to side effects, lack of ef-
fect or patient non-adherence’ [51]. In this study, these
events are being recorded and will be combined into a
composite outcome.Adherence will be reported as adherence in the group
eligible to be adherent (that is, still meant to be taking
the medicine). We will also report patients referred back
to the GP (whether a new medicine is prescribed or not)
as a separate outcome. This information will be available
from the six week call for both intervention and current
practice arm.
A composite outcome that combines proportion of ad-
herent patients and patients appropriately referred back to
the GP will be derived and summary statistics presented.
Data for the economic analysis
Costs of the intervention
Costs will be incurred at the patient level, in delivering
the intervention. Variable costs refer to items where the
quantity of resources used is determined only by the
need for them as inputs to individual patient care. Vari-
able resource use associated with the interventions (time
spent, costs of telephone calls, printing and posting) will
be recorded for each patient. Fixed costs are those costs
that are not affected by patient activity in the short term.
UK standard costs will be used for unit costs. This may
somewhat over- or under-estimate local unit costs, but
allows explicit comparison of costs and local adjustments
can be made. Unit costs associated with the intervention
will be obtained from the Personal Social Services Re-
search Unit (PSSRU) [60], Department of Health reference
tables and other reference costs.
Clinical and economic impact of non-adherence
The trial will not observe patient outcomes and NHS
costs resulting from non-adherence to their newly pre-
scribed medicine. Rather, outcomes will be derived from
published evidence on the link between adherence im-
provement and impact on health. The NMS study is not
designed to calculate the impact of the intervention on
patient health outcomes, either in terms of sample size
or length of follow-up. Use of proxy measures such as
number of primary and secondary care contacts (hos-
pital admissions, accident and emergency visits and out-
patient visits) may be subject to difficulties if considered
as patient outcomes. This is because the intervention
may lead to increased NHS contact in the short term.
Thus, we will estimate the long-term effect of the ob-
served adherence improvements on patient outcomes
and NHS costs. Data on natural history of diseases,
treatment effectiveness, resource use, and health status
(utility) will be obtained from published literature to
populate the model.
We will develop at least one treatment pathway model
for each of the four treatment groups targeted by NMS,
encompassing the consequences of being adherent or
non-adherent (see Figure 3). A common generic approach
will be used to develop the models. We will undertake the
Figure 3 Decision-analytic model for NMS economic evaluation.
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NHS in terms of the direct costs of providing an interven-
tion to improve medicines adherence in chronic illnesses
and the long-term costs of managing the conditions for
adherent and non-adherent patients (to estimate cost of
non-adherence).
Markov models will be designed and populated, in-
corporating the measures of uncertainty around the
point estimates, to conduct probabilistic sensitivity ana-
lysis. The UK Treasury recommended 3.5% discount rate
for both costs and outcomes will be used.
Literature review will be used to obtain published util-
ity weights to allow quality adjusted like year (QALY)
generation and cost utility analysis. The baseline Euro-
Qol 5D-3 L (EQ-5D) in our trial cohort will be incorpo-
rated into the QALY generation.
We will model the effect of the observed adherence
improvements on patient outcomes and NHS costs.
Probability, resource use and health status (utility) data
will be obtained from published literature to populate
the model.
Data for the qualitative study
It is anticipated that data for the qualitative study will be
obtained from 20 pharmacy profiles, 12 patient tracking,
24 patient interviews (12 for each NMS and current prac-
tice arm), 24 pharmacist interviews and eight GP inter-
views. Interviews will incorporate a range of patient and
professional views and will be digitally recorded and tran-
scribed. All accompanying field notes will be retained.Adverse events
The nature of the study presents a low risk to partici-
pants. In the unlikely event of a suspected adverse event,
these will be reported to the study principal investigator
and appropriate action taken on a case-by-case basis. All
adverse events will be reported to the study sponsor.
Sample size
The estimated change in prevalence of non-adherence
behavior (primary outcome) is expected to fall from 20%
to 10%. A sample size of 250 patients/arm is sufficient to
detect this change with 80% power, 5% significant level
(two-tailed) at a projected 20% drop-out rate. Therefore,
the total number of patients to be recruited for the RCT
is 500 patients.
Data obtained a few months post-NMS implementa-
tion indicated that on average, two NMS consultations
were initiated per pharmacy per week. It was initially es-
timated that on average there will be 52 eligible patients
per pharmacy in six months. Based on the assumption
that 50% of eligible NMS patients consent to be part of
the study, there will be 26 in each pharmacy over the re-
quired six months.
Revision of clinical site recruitment strategy
To deliver the sample as quickly as possible, patients
were to be recruited from 20 pharmacies which, assum-
ing the above drop-out rate, would deliver 520 patients
within six months. However, of 24 pharmacies initially
recruited, at least ten have not delivered patients to the
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declining to be in the study. Therefore, we are currently
replacing these pharmacies with ‘NMS-active’ pharmacies.
The pharmacy profiling has provided insights into the rea-
sons that affect service uptake and facilitators to recruit-
ment to the study. This has enabled us to develop a site
suitability survey to better identify more appropriate and
potentially more successful pharmacy sites for recruitment
(see Additional file 1: Table S1).
Compliance
We recognize that it can be a challenge to encourage
community pharmacies and patients using community
pharmacies to engage in interventions. We believe that
the risks of non-compliance will be minimized by pro-
viding pharmacies with clear information on what the
study involves, providing access to members of the re-
search team to answer queries and address problems ex-
perienced by the pharmacies.
Likely rate of loss to follow-up
In the original work, 20% patients withdrew from the
study due to a range of reasons [51]. The main reason
was that the patients in the intervention arm were re-
ferred back to the GP by the pharmacist due to side ef-
fects, lack of effect or patient non-adherence. In this
study, these events are being recorded and will be com-
bined into a composite outcome. Loss to follow-up for
other reasons is expected to be less than 10%.
Withdrawal of patients from the study
A patient will be considered to have withdrawn from the
study if the study team receives any notification that the
patient wishes to withdraw. This notification might
come from the patient themselves, the patient’s repre-
sentative or from the patient’s pharmacist. We have
accounted for withdrawal in our sample size calculations
to minimize the effect on the analysis.
As the NMS is a nationally available service which all
patients have the right to receive, some patients allo-
cated to the current practice study arm may decide post-
randomization that they still wish to receive the NMS.
Should this occur this will be counted as a withdrawal at
randomization. If a patient ‘loops’ through the NMS due
to referral back to their GP or addition/change of medi-
cation (which may mean they received a second new
medicine so will start at the beginning of the NMS for
this medicine), this patient will continue in the RCT/
study as normal. The interaction with the GP and/or
change in medication will be noted by the researchers.
Patient/public involvement
AC is co-investigator on the project and is an equal
member of the team. By attending monthly meetings inperson, he has been able to challenge, input and advise
the project at every step, bringing his experience and ex-
pertise of both the world outside academia and his time
living with a long-term condition, to the work. AC was
also involved in delivering training to the NMS study
pharmacists and in organizing the stakeholder day. We
have had further input from a group of patient represen-
tatives in development of:
 the NMS evaluation study application submitted to
the DOH
 the content of materials used for patient recruitment
(mainly information sheets and consent forms)
 data collection forms used during the follow-up tele-
phone calls
 the diary for collecting health care resource use data
 the presentation used for the NMS study pharmacist
training day
 training of the NMS study pharmacist
 frequently asked questions for the study website
We have a website that provides information to inter-
ested parties. (http://www.nottingham.ac.uk/).
Statistical analysis
Descriptive analyses
Continuous data will be explored using means and
standard deviations (SD) if approximately normally dis-
tributed and medians and inter-quartile ranges (IQR) if
non-normally distributed. Categorical data will be de-
scribed using frequencies and percentages.
Comparing baseline characteristics between treatment arms
The following characteristics will be described by treat-
ment arm: patient age, gender geographic location, dis-
ease group and diagnosed person years; (Additional file 1:
Table S2).
Comparisons between treatment arms
An intention-to-treat analysis will be used such that pa-
tients will be analyzed in the arms they were allocated
to, regardless of whether they received the intervention
or not [61,62].
Data analysis will be conducted by the research team
and by the study statistician (RM). To compare adher-
ence rates, differences in categorical variables will be an-
alyzed using the chi-squared test or Fisher’s exact test as
appropriate. The relationship between non-adherence
and treatment group will be investigated using logistic
regression models to adjust for interaction with chronic
disease and other potential confounders. The signifi-
cance of the variables in the model will be assessed using
the Wald chi-squared test and determination of odds ra-
tios (ORs) with associated 95% confidence intervals
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the Hosmer and Lemeshow test.
Data collected from the study will be compared with
anonymized data from available NMS national data sets.
This will facilitate generalizability of the findings.
Statistical significance will be assessed at the 5% (two-
sided) level. All statistical analyses will be conducted
using SPSS16 (SPSS IBM United Kingdom Limited, PO
Box 41, North Harbour, Portsmouth, Hampshire, PO6
3 AU)and STATA 11.0 (STATA: Timberlake Consultants
Limited B3 Broomsleigh Business Park Worsley Bridge
Road, London SE26 5BN United Kingdom) [63].
Primary outcome
The primary outcomes will report on the impact of the
intervention on adherence to prescribed medicines.
If any patients are lost to follow-up, a sensitivity ana-
lysis will be undertaken [61,62].
Secondary outcome measures
We acknowledge the potential for type 1 errors associ-
ated with significance testing for multiple end points.
We will therefore consider our analyses of secondary
outcome measures to be partly exploratory in nature,
and partly confirmatory of our findings for the primary
outcome measures.
 process measures: parameters from NMS audit data
set
 cognitive and behavioral outcome (self-reported
adherence (NMS question and MMAS-8))
 number of medicines-related problems reported by
patients, and resolved
 adverse events and NHS contacts associated with
adverse events
 health status (EQ-5D)
 resource use and costs
 length of initial and subsequent NMS consultations
 NHS contact (primary and secondary care)
 non-medical costs
Within trial analysis of costs
Costs calculated in the trial analysis will be the cost of
intervention for each patient enrolled in the trial for
both treatment arms. These data will be presented separ-
ately for the two treatment arms. Comparisons between
treatment arms at patient level will be made using a
two-sample t-test on the original dataset, or on a boot-
strapped dataset, depending on the normality of the dis-
tribution of costs [64].
Sub-group analyses
Sub-group analyses [65] will only be undertaken for pri-
mary outcome measures. Analyses will be undertaken toassess whether the effect of the intervention varies by dis-
ease type, age, gender, pharmacy type, pharmacy location,
time since diagnosis, number of other medicines pre-
scribed, and deprivation index. Treatment arm and the
(continuous) covariate of interest will be added into the
regression model [65]. Where there is evidence of non-
linearity, this will be investigated and appropriate transfor-
mations will be performed. Significance will be assessed
based on likelihood ratio tests with a P value of < 0.05
taken as significant and P values between 0.05 and 0.1 de-
scribed as there being ‘some evidence’ for an interaction.
Missing data
A complete case analysis will be undertaken with a range
of approaches for undertaking sensitivity analyses to as-
sess the robustness of the findings with respect to miss-
ing data.
Economic analysis
A standard approach to economic analysis will be ap-
plied [66]. We propose to undertake the economic
analyses from the perspective of the NHS in terms of
the direct costs of providing an intervention to im-
prove medicines adherence in primary care, and the
costs of managing diseases for adherent and non-
adherent patients.
Comparators and key parameters under investigation
The evaluation will compare the NMS intervention
with current practice. The main outcome of the eco-
nomic analysis is cost per QALY gained. We will exam-
ine the differences in overall NHS costs and in QALYs
gained between NMS intervention and current practice
patient groups. Additionally, trial-based economic ana-
lysis will be conducted and cost per extra adherent pa-
tient will be estimated.
Sample size for the economic analysis
The study cannot be powered to detect differences in
costs because there is no prior study upon which to base
a power calculation.
Time horizon (follow-up period)
Adherence rates in both groups will be followed up for
six months following the completion of the intervention.
The Markov models will follow up patients for long-
term horizon (to capture all the relevant cost and out-
come consequences for each disease group). Life time
horizon will be considered.
Modeling the effect of non-adherence in each disease
group
Each disease-specific Markov model will be populated
with transition probability, cost and health status data to
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patients and in a cohort of non-adherent patients.
Estimating the cost effectiveness of the NMS intervention
Trial-based cost-effectiveness analysis (short-term economic
evaluation)
Trial-based economic evaluation will be conducted. The
adherence measures, intervention costs, and total costs
incurred during the trial horizon will be generated at pa-
tient level. Then, the adherence rates in the NMS and
current practice arms and cost per extra adherent pa-
tient will be calculated. Both deterministic and probabil-
istic incremental economic analyses will be carried out
using the adjusted cost and outcome data, in combin-
ation with the NMS intervention costs.
The incremental cost per extra adherent patient gener-
ated by the NMS intervention over current practice will
be calculated using the following equation:
ICER ¼ CostNMS–CostCurrent practice
 
=
rNMS–rCurrent practice
 
;
where rNMS, rCurrent practice is the proportion of adherent
patients in the NMS arm, and current practice arm, re-
spectively. Statistical analysis is not appropriate to test
the robustness of ICER. It is not possible to generate
95% confidence intervals around ICERs because the ratio
of two distributions does not necessarily have a finite
mean, or therefore, a finite variance [67]. Therefore, gen-
eration of a bootstrap estimate of the ICER sampling
distribution to identify the magnitude of uncertainty
around the ICERs is required. Bootstrapping with replace-
ment will be employed, utilizing Microsoft Excel (Micro-
soft Campus, Thames Valley Park, Reading, Berkshire,
RG6 1WG), using a minimum of 5,000 iterations. These
incremental costs and outcomes will be plotted on cost ef-
fectiveness plane, uncertainty around ICER will be investi-
gated and cost effectiveness acceptability curves (CEACs)
[68,69] will be constructed.
Cost-utility analysis (long-term economic evaluation)
Combining the NMS trial results with the disease-
specific models will allow us to estimate the costs and
outcomes associated with the NMS intervention versus
current practice.
The adherence rates for each disease group occur-
ring in the NMS and current practice arms will be
combined with the disease-specific Markov models
(see Figure 3). The incremental costs and outcomes as-
sociated with each disease group will be estimated
based on trial combined with economic model. This
will allow us to generate the incremental effect of the
NMS intervention on the costs and outcomes for eachdisease group, and overall (for the population for
which NMS service is targeted).
Incremental economic analyses will be carried out using
the adjusted cost and outcome data (observed in the trial)
in combination with the NMS intervention costs, and
long-term costs and health effects (estimated using Mar-
kov models). This will generate the estimates of the overall
costs and health outcomes, measured by QALY gained, for
the NMS and the current practice arms.
The incremental cost per extra QALY generated by the
NMS intervention over current practice will be calcu-
lated using the following equation:
ICER ¼ CostNMS–CostCurrent practice
 
=
QALYNMS–QALYCurrent practice
 
:
Sensitivity and scenario analysis
Sensitivity analysis is required to assess the level of un-
certainty in the data collected within the trial and subse-
quent internal robustness of the results.
Several deterministic one-way sensitivity analyses will
be conducted (testing the impact of key uncertain pa-
rameters on the cost-utility result). Scenario analyses will
be proposed and discussed, alternative key assumptions
will be tested.
Probabilistic sensitivity analysis (PSA) will be con-
ducted for base-case scenario, main alternative scenarios
(and one-way sensitivity analyses).
Monte Carlo simulation will be applied for sampling
incremental costs and QALY, using Tree Age Pro (Tree-
Age Software, Inc., 888-TreeAge -or- +1 413-458-0104,
One Bank Street Williamstown, MA, 01267 USA) (at
least 1,000 samples). Uncertainty around input parame-
ters will be modeled in a standard way: appropriate
probability distributions will be assumed for cost, utility,
probabilities and ratios [70].
Cost effectiveness acceptability curves (CEACs) [68]
will be constructed to express the probability that the
cost per QALY gained (y-axis) is cost effective as a func-
tion of the decision-maker’s ceiling cost effectiveness ra-
tio (λ) (x-axis) for base-case, sensitivity and scenario
analyses [69].
The incremental net monetary benefit (INB) will be
estimated from the incremental costs and QALYS for
NMS compared with current practice using the formula:
INB λð Þ ¼ λ QALYNMS–QALYCurrent practice
 
− CostNMS–CostCurrent practice
 
The incremental net benefit approach will be used due
to well-known problems associated with incremental
cost effectiveness ratios (ICERs) when bootstrap repli-
cates cover all four quadrants of the cost effectiveness
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calculated for a threshold range from £0 to £160,000
using increments of £10,000.
Format of tables for publishing the main trial results and
within trial economic analysis
The format of tables for publishing the main trial results
and economic analysis is shown in Additional file 1:
Table S2.
Qualitative study
Qualitative data analysis will start during the early stages
of data collection and proceed iteratively so that emergent
findings are incorporated into subsequent data collection,
including the revision of data collection methods, such as
interview topic guides. All pharmacy profile observations
will be recorded in field notes and subsequently typed up.
All interviews will be transcribed verbatim. The data will
be then imported into qualitative analysis package NVivo;
QSR International Pty Ltd. Version 9, 2010 (QSR Inter-
national (UK) Limited, Warrington, Cheshire, WA2 7LT,
United Kingdom) for the purpose of coding and thematic
analysis. This will involve initial reading and re-reading of
the transcribed data by multiple members of the research
team to identify common codes and categories. These
codes will be compared for their internal consistency and
boundaries. A coding framework will be constructed itera-
tively and two members of the research team will system-
atically code data according to this framework. Coded
extracts will be compared and differences of opinion dis-
cussed until agreement is reached. Actively searching for
disconfirming data will be undertaken as well as regular
detailed discussions amongst the qualitative researchers.
To enhance the consistency of analysis, review meetings
will be held with a third researcher (JW) who will oversee
the process and negotiate consensus on the final thematic
codes assigned to each response.
Consideration will then be given to how these issues
group together in broader themes related to the research
objectives. The principle of constant comparison will be
used to test and refine the empirical conceptual consistency
of codes and themes which were synthesized and narrated
using a technique similar to that used by Ziebland and
McPherson (2006) [73].
Trial organization
Professor Elliott and Dr Boyd will have overall responsi-
bility for the day-to-day management of the trial and
Professor Waring will have overall responsibility for the
qualitative workstream. Professor Elliott will have re-
sponsibility for the economic analysis. Mr Mehta is the
trial statistician.
A Project Management Group will be meeting monthly
throughout the study to help ensure that all trial activitiesare organized according to the protocol and within the
timescales set out in the original application for funding,
will monitor and supervise the trial and comment on any
proposed amendments to the protocol.
The NMS Evaluation Advisory Group (NEAG) is headed
by Professor Nick Mays. The trial statistician will report to
the NEAG, which will be responsible for reviewing the
data from the trial. The NEAG has agreed to operate
within the framework suggested in the MRC Guidelines
for Good Clinical Practice in Clinical Trials [74].
Ethical aspects
The clinical trial will be conducted according to the
Helsinki Declaration [70], the GCP Guidelines [75] and
NHS Research Governance requirements. Patients agree-
ing to participate in the study have provided written in-
formed consent in a form designed for such purpose.
The patient may refuse to continue participating in the
study at any time after providing his/her consent. The
information generated by the study will be confidential
and limited to the purposes stipulated in the protocol.
The study was given a favorable opinion on 2 May 2012
by the National Research Ethics Service (NRES) Black
Country Research Ethics Committee (12/WM/0096).
All staff involved in data collection will have approval
from the appropriate local NHS research and develop-
ment offices.
The study was registered with the ClinicalTrials.gov
trials database on 19 June 2012. Trial reference number
NCT01635361 (http://clinicaltrials.gov/ct2/show/NCT01
635361).
The study was registered with the Current Controlled
trials database on 5 July 2012. Trial reference number
ISRCTN 23560818 (http://www.controlled-trials.com/
ISRCTN23560818/; DOI 10.1186/ISRCTN23560818).
This study is registered with the UK Clinical Research
Network (UKCRN) study 12494 (http://public.ukcrn.org.
uk/Search/StudyDetail.aspx?StudyID=12494).
Study timeline
Trial start: January 2012
Start of baseline data collection and interventions in
pharmacies: August 2012
End of interventions in pharmacies: September 2013
End of six month follow-up data collection: March
2014 (one month after official funding ends)
Start of data analysis: September 2013
Planned study end date: February 2014
Duration: 26 months
Discussion
As the NMS intervention is an advanced service being
delivered by appropriately qualified pharmacists, we did
not expect non-compliance with the intervention to be a
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fering the service to a limited number of patients, which
has affected our patient recruitment rate and has required
further site recruitment. We have also revised recruitment
targets for individual pharmacies and developed a site suit-
ability survey. On-going support provided to sites includes
regular visits to sites have been made by members of the
research team. Sites have also been kept up-to-date with
recruitment progress through newsletters.
One strength of this study is the substantial qualitative
workstream, supplemented by engagement and imple-
mentation activity. Many studies of pharmacy interven-
tions have not included qualitative work. Qualitative
work will enable us to learn about how this service is ac-
tually being implemented in practice and will enable us
to explain the quantitative results we obtain. We will be
carrying out stakeholder days where we will be inviting
patients, service providers and commissioners to attend,
to obtain views on the NMS in particular, and on man-
aging medicines for long-term conditions in general.
Trial status
At the time of submission of this article, 58 pharmacies
have been recruited into the study. Seventy pharmacists
have been trained and 502 patients have been recruited (4
October 2013). At the time of submitting this protocol,
analysis of quantitative data had not been undertaken.
Additional file
Additional file 1: File name: Elliott Additional file 1. File format: MS
Word (.doc). Title of data: site suitability survey and outline of results
tables. Description of data: two tables.
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